4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide profile

4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide: mono-N-dealkylated disopyramide metabolite; RN given refers to parent cpd; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	107858
CHEMBL ID	1307
CHEBI ID	174148
MeSH ID	M0096275

Synonym
CHEBI:174148
2-phenyl-4-(propan-2-ylamino)-2-pyridin-2-ylbutanamide
4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide
alpha-(2-((1-methylethyl)amino)ethyl)-alpha-phenyl-2-pyridineacetamide
2-pyridineacetamide, alpha-(2-((1-methylethyl)amino)ethyl)-alpha-phenyl-
mono-isopropyl-disopyramide
sc 24566
38236-46-3
CHEMBL1307
n-monodeisopropyl disopyramide
2-phenyl-4-(propan-2-ylamino)-2-(2-pyridinyl)butanamide
2-phenyl-4-(propan-2-ylamino)-2-pyridin-2-yl-butanamide
A825030
unii-t4h9flx72t
t4h9flx72t ,
4-isopropylamino-2-phenyl-2-(2-pyridyl)butyramide
SC-24566 ,
n-de(isopropyl)disopyramide
disopyramide phosphate impurity c [ep impurity]
mono-n-desisopropyldisopyramide
2-pyridineacetamide, .alpha.-(2-((1-methylethyl)amino)ethyl)-.alpha.-phenyl-
AKOS025395154
4-(isopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide
mono-isopropyl disopyramide
Q27289658
2-phenyl-4-[(propan-2-yl)amino]-2-(pyridin-2-yl)butanimidic acid
DTXSID00959180

Excerpt	Reference	Relevance
" On the basis of the pharmacokinetic changes observed (and provided that plasma protein binding is unchanged), D oral dose should be reduced by 1/3, without modifying the dosage interval."	( Disopyramide pharmacokinetics in the elderly after single oral administration. Donatella, P; Gabriella, C; Raffaella, M; Roberto, P; Sergio, B; Vitaliano, B, 1988)	0.27

Excerpt	Relevance	Reference
" On the basis of the pharmacokinetic changes observed (and provided that plasma protein binding is unchanged), D oral dose should be reduced by 1/3, without modifying the dosage interval."	( Disopyramide pharmacokinetics in the elderly after single oral administration. Donatella, P; Gabriella, C; Raffaella, M; Roberto, P; Sergio, B; Vitaliano, B, 1988)	0.27

Class	Description
organonitrogen compound	Any heteroorganic entity containing at least one carbon-nitrogen bond.
organooxygen compound	An organochalcogen compound containing at least one carbon-oxygen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID79032	Inhibitory concentration of guinea pig ileum longitudinal muscle strips to antagonize electrically stimulated contractions	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide.
AID79373	Mean dissociation constant was measured for acetylcholine-induced contractions	1981	Journal of medicinal chemistry, May, Volume: 24, Issue:5	Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	23 (67.65)	18.7374
1990's	9 (26.47)	18.2507
2000's	2 (5.88)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (8.11%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (2.70%)	4.05%
Observational	0 (0.00%)	0.25%
Other	33 (89.19%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
histamine [no description available]	1.96	1	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	12.13	34	3	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	1.96	1	0	acetamides; benzamides	anti-arrhythmia drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	1.96	1	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	1.96	1	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	1.97	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
disopyramide, (s)-isomer [no description available]	1.96	1	0
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	1.96	1	0
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	1.96	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
cellulose DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.	1.97	1	0	glycoside

Condition	Relationship Strength	Studies	Trials
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.96	1	0
ANS (Autonomic Nervous System) Diseases [description not available]	2.04	1	0
Asialia [description not available]	2.04	1	0
Urination Disorders Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.	2.04	1	0
Xerostomia Decreased salivary flow.	2.04	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.96	1	0
Fasting Hypoglycemia HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.	1.98	1	0
Chronic Kidney Failure [description not available]	1.98	1	0
Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.	1.98	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	1.98	1	0
Cardiovascular Pregnancy Complications [description not available]	1.97	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.97	1	0
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	1.97	1	0
Chronic Illness [description not available]	3.35	1	1
Arrhythmia [description not available]	3.35	1	1
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	3.35	1	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.35	1	1

4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide

Description

Cross-References

Synonyms (27)

Research Excerpts

Pharmacokinetics

Dosage Studied

Drug Classes (2)

Bioassays (2)

Research

Studies (34)

Market Indicators

Research Demand Index: 10.32

Study Types